Skip to content
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Hematology

How Is Peripheral Neuropathy Pain Treated in Amyloidosis?

At a Glance

Treatment for amyloidosis-related nerve pain aims to slow further nerve damage and ease symptoms. Care is individualized by amyloidosis type and kidney, heart, and blood-pressure health, with daily foot protection, physical therapy, and fall prevention.

Peripheral neuropathy—which often causes burning pain, numbness, and tingling in the feet—is one of the most challenging symptoms of amyloidosis. However, nerve pain in people with amyloidosis can also be caused by other factors, such as diabetes, vitamin deficiencies, or even the medications used to treat the amyloidosis itself [1].

Managing this pain requires a two-part approach: using specific pain medications to relieve your daily discomfort, and using disease-modifying treatments to stop the amyloid protein from causing further nerve damage. Alongside medication, practical steps like proper footwear and physical therapy are essential for protecting your feet and preventing falls.

Stopping the Nerve Damage: Disease-Modifying Treatments

Treating the underlying cause of your amyloidosis is the most effective way to prevent peripheral neuropathy from getting worse [2]. The correct approach depends on which type of amyloidosis you have, your specific symptoms, and your overall health [2]:

  • Hereditary ATTR (hATTR) amyloidosis: For this genetic type, medications called gene silencers (such as patisiran, vutrisiran, and inotersen) reduce the liver’s production of the transthyretin (TTR) protein before it can misfold and damage nerves [3][4]. Clinical trials show these therapies can slow or halt progressive nerve damage [5]. While some patients experience improvements in neurologic function over time, existing nerve damage may be permanent, and results vary depending on how early treatment begins [6]. These drugs require careful monitoring by your care team, such as taking prescribed vitamin A supplements (for gene silencers) or monitoring kidney and platelet function (for inotersen) [4][7].
  • AL (Light Chain) amyloidosis: Treatment involves therapies directed at the plasma cells (a type of white blood cell in the bone marrow), such as combination chemotherapy regimens, targeted immunotherapies (like daratumumab), or stem cell transplants in carefully selected patients [8][9]. The goal is to quickly lower the production of toxic light chains (abnormal antibody fragments) [10]. Notably, a common AL treatment called bortezomib can actually cause or worsen peripheral neuropathy [1][11]. If you develop nerve pain, your hematology team may adjust your dose or switch your regimen to protect your nerves—but you should never stop or change your regimen without their guidance [1].

Medications to Calm Nerve Pain

While disease-modifying therapies treat the underlying condition, they do not provide immediate pain relief. For burning or shooting pain, doctors prescribe medications that change how damaged nerves send pain signals to your brain [12]. These medications can take days or weeks to work and require gradual dose adjustments.

The safest option is highly individualized and must be chosen by your doctor based on your kidney function, heart health, and other conditions [13]:

  • Nerve pain medications (Gabapentinoids): Drugs like gabapentin and pregabalin are common options for neuropathic pain [13][12]. They can significantly reduce nerve pain, but they must be adjusted carefully based on your kidney function [14]. Side effects can include dizziness, sleepiness, and leg swelling, which can compound balance issues and increase fall risk when mixed with other sedating medicines [14].
  • Antidepressants for pain: Medications such as duloxetine (an SNRI, or serotonin-norepinephrine reuptake inhibitor) or amitriptyline (a tricyclic antidepressant) are also effective options [12][13]. However, they must be used carefully. Duloxetine can cause orthostatic hypotension (a drop in blood pressure upon standing) and is unsuitable for those with severe kidney or liver disease [15]. Amitriptyline is generally avoided if you have autonomic neuropathy (damage to the nerves controlling involuntary functions like blood pressure or heart rate), as it can worsen sudden drops in blood pressure, cause severe sedation, and affect heart rhythms [16].
  • Topical treatments: Numbing patches (like 5% lidocaine) can be applied directly to intact skin on the feet for localized pain [12]. Because very little of the drug enters the bloodstream, the risk of systemic side effects is low [17]. Note that high-strength capsaicin patches (8%) are different; they cause intense burning initially and must be applied in a clinic by a healthcare professional [12]. Never apply any patch to an ulcer, open wound, or infected skin.
  • Opioids: Strong pain medications like tramadol or methadone are typically avoided or used only as a last resort [13]. Tramadol carries risks of seizures and dangerous interactions with antidepressants, while methadone requires specialist prescribing and monitoring for dangerous heart rhythm effects [18]. Opioids also cause sedation, breathing depression, constipation, and increase the risk of falls [19].

Protecting Your Feet and Preventing Falls

Because peripheral neuropathy causes numbness (loss of protective sensation), you might not feel a cut or sore. Drawing on standards established for diabetic neuropathy care, taking strict precautions can help prevent small injuries from developing into serious ulcers [20].

Daily Foot Care Action Plan

  • Inspect daily: Check the tops and bottoms of your feet daily. Use a mirror or ask a caregiver to help if you cannot see the bottoms [20].
  • Check inside your shoes: Always feel the inside of your shoes for pebbles or rough seams before putting them on [20].
  • Avoid heat damage: Do not use heating pads or very hot water on your feet, as you may not feel a burn [20].
  • Do not perform “bathroom surgery”: Never cut calluses yourself or use over-the-counter chemical corn removers. Regular visits to a podiatrist are strongly recommended [20].
  • Wear protective footwear: Never walk barefoot. Wear shoes with a wide toe box, good support, and no pressure points [21][22].
  • Urgent Care: Contact your clinical team immediately if you notice a new open wound, blister, severe swelling, redness, warmth, foul odor, or black/blue discoloration on your foot.

Fall Prevention and Balance

Numbness impairs your balance, but fall risk in amyloidosis is also heavily influenced by orthostatic hypotension (a sudden drop in blood pressure when standing, causing dizziness) and side effects from sedating pain medications [23][24].

  • Physical therapy: Ask your doctor for a referral to a physical therapist for a supervised balance and gait assessment [25]. Do not try to challenge your balance on your own or walk with your eyes closed.
  • Walking aids: If you are stumbling or feel unstable, a therapist can properly fit you for orthotics (custom shoe inserts or joint supports), a cane, or a walker [26].
  • Home modifications: An occupational therapist can evaluate your home and recommend removing throw rugs, improving lighting, or adding grab bars to make navigation safer [27].

Common questions in this guide

What is the main way to treat peripheral neuropathy pain in amyloidosis?
Treatment usually combines therapy for the specific type of amyloidosis with medicine for nerve pain. Gene-silencing drugs may slow nerve damage in hereditary ATTR amyloidosis, while AL amyloidosis treatment lowers harmful light-chain production. Physical therapy, protective footwear, and fall-prevention measures help protect function.
Can my amyloidosis treatment make nerve pain worse?
Yes. Bortezomib, a medicine used for AL amyloidosis, can cause or worsen peripheral neuropathy in some people. Tell your hematology team about new or worsening pain, numbness, or weakness; they may adjust the dose or change treatment, but you should not stop it on your own.
Which pain medicines are used for amyloidosis-related nerve pain?
Common options include gabapentin or pregabalin, and some people benefit from duloxetine or amitriptyline. A lidocaine patch may help localized pain on intact skin, while high-strength capsaicin patches are applied by a clinician. The safest choice depends on kidney function, heart health, blood pressure, other medicines, and fall risk.
How can I protect my feet if amyloidosis has caused numbness?
Inspect the tops and bottoms of your feet every day, check inside your shoes, avoid barefoot walking and very hot water, and wear supportive shoes with room for your toes. Do not cut calluses yourself or use chemical corn removers. Contact your clinical team promptly for an open wound, blister, redness, warmth, foul odor, severe swelling, or black or blue skin.
How can I lower my risk of falls with amyloidosis neuropathy?
Numbness, dizziness from a blood-pressure drop when standing, and sedating medicines can all increase fall risk. A physical therapist can assess your balance and fit a cane, walker, or orthotic if needed, while an occupational therapist can suggest safer lighting, fewer trip hazards, and grab bars at home. Do not test your balance by walking with your eyes closed.
Could something besides amyloidosis be causing my nerve pain?
Yes. Diabetes, vitamin deficiencies, and medicines used to treat amyloidosis can also contribute to peripheral neuropathy. Ask your care team to review your symptoms, medicines, blood pressure, kidney function, and relevant vitamin levels before changing treatment.
What monitoring do gene-silencing treatments require?
People taking gene-silencing treatment for hereditary ATTR amyloidosis may need prescribed vitamin A supplementation and regular monitoring. Inotersen requires attention to kidney function and platelet counts. Follow the specific plan from your care team rather than taking supplements or changing doses on your own.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific type of amyloidosis is causing my peripheral neuropathy, or could other factors like my chemotherapy, diabetes, or vitamin levels be contributing?
  2. 2.Given my kidney function, heart health, and blood pressure, what is the safest pain medication for me to try?
  3. 3.Are any of my current treatments (like bortezomib) or pain medicines increasing my risk of falls or nerve damage?
  4. 4.Should I be evaluated by a podiatrist for specialized footwear to protect my numb feet?
  5. 5.Can you refer me to a physical therapist for a supervised balance assessment and to evaluate if a walking aid would help?
  6. 6.If I am taking a TTR-lowering medication (gene silencer), what is my specific plan for vitamin A supplementation and monitoring?

References

References (27)
  1. 1

    Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.

    Thimm A, Carpinteiro A, Oubari S, et al.

    Journal of the neurological sciences 2022; (440()):120341 doi:10.1016/j.jns.2022.120341.

    PMID: 35872471
  2. 2

    Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.

    Gertz MA, Dispenzieri A

    JAMA 2020; (324(1)):79-89 doi:10.1001/jama.2020.5493.

    PMID: 32633805
  3. 3

    Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

    Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.

    The New England journal of medicine 2018; (379(1)):11-21 doi:10.1056/NEJMoa1716153.

    PMID: 29972753
  4. 4

    Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

    Benson MD, Waddington-Cruz M, Berk JL, et al.

    The New England journal of medicine 2018; (379(1)):22-31 doi:10.1056/NEJMoa1716793.

    PMID: 29972757
  5. 5

    Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

    González-Duarte A, Berk JL, Quan D, et al.

    Journal of neurology 2020; (267(3)):703-712 doi:10.1007/s00415-019-09602-8.

    PMID: 31728713
  6. 6

    Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.

    Quan D, Obici L, Berk JL, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2023; (30(1)):49-58 doi:10.1080/13506129.2022.2118043.

    PMID: 36120830
  7. 7

    A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.

    Liu Y, Li H, Hu C, et al.

    Frontiers in pharmacology 2024; (15()):1368244 doi:10.3389/fphar.2024.1368244.

    PMID: 38873427
  8. 8

    Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

    Blair HA

    Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.

    PMID: 35416593
  9. 9

    Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.

    Sanchorawala V, Boccadoro M, Gertz M, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(1)):1-7 doi:10.1080/13506129.2021.2002841.

    PMID: 34783272
  10. 10

    Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

    Ikura H, Endo J, Kitakata H, et al.

    International journal of molecular sciences 2022; (23(11)) doi:10.3390/ijms23116336.

    PMID: 35683015
  11. 11

    The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.

    Liu B, Bai M, Wang Y, et al.

    European journal of internal medicine 2019; (69()):32-41 doi:10.1016/j.ejim.2019.08.011.

    PMID: 31447275
  12. 12

    Neuropathic pain: Evidence based recommendations.

    Moisset X

    Presse medicale (Paris, France : 1983) 2024; (53(2)):104232 doi:10.1016/j.lpm.2024.104232.

    PMID: 38641202
  13. 13

    Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis.

    Soliman N, Moisset X, Ferraro MC, et al.

    The Lancet. Neurology 2025; (24(5)):413-428 doi:10.1016/S1474-4422(25)00068-7.

    PMID: 40252663
  14. 14

    Gabapentin for chronic neuropathic pain in adults.

    Wiffen PJ, Derry S, Bell RF, et al.

    The Cochrane database of systematic reviews 2017; (6()):CD007938 doi:10.1002/14651858.CD007938.pub4.

    PMID: 28597471
  15. 15

    The Pharmacological Therapy of Chronic Neuropathic Pain.

    Binder A, Baron R

    Deutsches Arzteblatt international 2016; (113(37)):616-625.

    PMID: 27697147
  16. 16

    [Causes, spectrum, and treatment of the diabetic neuropathy].

    Dohrn MF, Winter N, Dafotakis M

    Der Nervenarzt 2020; (91(8)):714-721 doi:10.1007/s00115-020-00948-3.

    PMID: 32647958
  17. 17

    Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence.

    Sommer C, Cruccu G

    Journal of pain and symptom management 2017; (53(3)):614-629 doi:10.1016/j.jpainsymman.2016.09.015.

    PMID: 28042075
  18. 18

    Methadone in Cancer Pain.

    Ramkiran S, Thota RS

    Indian journal of palliative care 2020; (26(2)):215-220 doi:10.4103/0973-1075.285690.

    PMID: 32874036
  19. 19

    Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study.

    Balasundaram MK, Kannauje PK, Dhaneria S, Singh A

    Annals of neurosciences 2026; (33(1)):29-36 doi:10.1177/09727531241243126.

    PMID: 39544662
  20. 20

    Preventing diabetes-related foot ulcers through early detection of peripheral neuropathy.

    McMorrow R, Nube VL, Manski-Nankervis JA

    Australian journal of general practice 2022; (51(11)):833-838 doi:10.31128/AJGP-06-22-6456.

    PMID: 36309996
  21. 21

    Footwear in the causation and prevention of foot ulcers in diabetes mellitus.

    Premkumar R, Rajan P, Rima J, Richard J

    The National medical journal of India 2017; (30(5)):255-261 doi:10.4103/0970-258X.234391.

    PMID: 29916424
  22. 22

    Assessment of ulceration risk in diabetic individuals.

    Dutra LMA, Novaes MRCG, Melo MC, et al.

    Revista brasileira de enfermagem 2018; (71 Suppl 2()):733-739 doi:10.1590/0034-7167-2017-0337.

    PMID: 29791638
  23. 23

    Exercise Interventions for Individuals With Neurological Disorders: A Systematic Review of Systematic Reviews.

    Lai CH, Chen HC, Liou TH, et al.

    American journal of physical medicine & rehabilitation 2019; (98(10)):921-930 doi:10.1097/PHM.0000000000001247.

    PMID: 31206360
  24. 24

    Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.

    Palma JA, Gonzalez-Duarte A, Kaufmann H

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):33-44 doi:10.1007/s10286-019-00623-x.

    PMID: 31452021
  25. 25

    A Systematic Review of the Effect of Physical Rehabilitation on Balance in People with Diabetic Peripheral Neuropathy Who are at Risk of Falling.

    Alissa N, Shipper AG, Zilliox L, Westlake KP

    Clinical interventions in aging 2024; (19()):1325-1339 doi:10.2147/CIA.S459492.

    PMID: 39050517
  26. 26

    Epidemiology and Functional Impact of Early Peripheral Neuropathy Signs in Older Adults from a General Population.

    Bronge W, Lindholm B, Elmståhl S, Siennicki-Lantz A

    Gerontology 2024; (70(3)):257-268 doi:10.1159/000535620.

    PMID: 38043521
  27. 27

    The Effect of Individualized Fall Prevention Programs on Community-Dwelling Older Adults: A Scoping Review.

    Boright LE, Arena SK, Wilson CM, McCloy L

    Cureus 2022; (14(3)):e23713 doi:10.7759/cureus.23713.

    PMID: 35510013

This page explains ways to manage amyloidosis-related nerve pain for informational purposes only and does not constitute medical advice. Your amyloidosis and pain-care teams should choose medicines and treatment changes based on your health.